Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Progressive multifocal leukoencephalopathy associated with ruxolitinib.

Literature DB >> 23841743

Progressive multifocal leukoencephalopathy associated with ruxolitinib.

Rowan Wathes, Simon Moule, Dragana Milojkovic.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2013 PMID： 23841743 DOI： 10.1056/NEJMc1302135

Source DB: PubMed Journal: N Engl J Med ISSN： 0028-4793 Impact factor: 91.245

Keyword Cloud
Cited

× No keyword cloud information.

53 in total

Review 1. Immunological Consequences of JAK Inhibition: Friend or Foe?

Authors: Donal P McLornan; Alesia A Khan; Claire N Harrison
Journal: Curr Hematol Malig Rep Date: 2015-12 Impact factor: 3.952

Review 2. Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.

Authors: Brady L Stein; Jason Gotlib; Murat Arcasoy; Marie Huong Nguyen; Neil Shah; Alison Moliterno; Catriona Jamieson; Daniel A Pollyea; Bart Scott; Martha Wadleigh; Ross Levine; Rami Komrokji; Rebecca Klisovic; Krishna Gundabolu; Patricia Kropf; Meir Wetzler; Stephen T Oh; Raul Ribeiro; Rita Paschal; Sanjay Mohan; Nikolai Podoltsev; Josef Prchal; Moshe Talpaz; David Snyder; Srdan Verstovsek; Ruben A Mesa
Journal: J Natl Compr Canc Netw Date: 2015-04 Impact factor: 11.908

Progressive multifocal leukoencephalopathy associated with ruxolitinib.

Review 1. Immunological Consequences of JAK Inhibition: Friend or Foe?

Review 2. Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.

Review 3. The Rationale for Immunotherapy in Myeloproliferative Neoplasms.

4. Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib.

Review 5. Efficacy of ruxolitinib for myelofibrosis.

Review 6. The emerging safety profile of JAK inhibitors in rheumatic disease.

Review 7. JAK2 inhibitors for myeloproliferative neoplasms: what is next?

8. Disseminated tuberculosis associated with ruxolitinib.

Review 9. Clinical potential of pacritinib in the treatment of myelofibrosis.

Review 10. Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.